Shivali S Joshi1,2, Shan Gao1,2, Eliana Castillo3, Carla S Coffin4,5. 1. Calgary Liver Unit, Division of Gastroenterology and Hepatology, Department of Medicine, Cumming School of Medicine, University of Calgary, 6D21, Teaching, Research and Wellness Building, 3280 Hospital Drive N.W., Calgary, AB, T2N 4Z6, Canada. 2. Department of Microbiology, Immunology and Infectious Diseases, Cumming School of Medicine, University of Calgary, Calgary, Canada. 3. Section of Maternal Fetal Medicine, Department of Medicine, Cumming School of Medicine, University of Calgary, Calgary, Canada. 4. Calgary Liver Unit, Division of Gastroenterology and Hepatology, Department of Medicine, Cumming School of Medicine, University of Calgary, 6D21, Teaching, Research and Wellness Building, 3280 Hospital Drive N.W., Calgary, AB, T2N 4Z6, Canada. cscoffin@ucalgary.ca. 5. Department of Microbiology, Immunology and Infectious Diseases, Cumming School of Medicine, University of Calgary, Calgary, Canada. cscoffin@ucalgary.ca.
Abstract
PURPOSE: HBV precore (PC) and basal core promoter (BCP) mutants are associated with liver disease severity, yet have been suggested to protect against HBV vertical transmission. HBV within peripheral blood mononuclear cells (PBMC) has been reported in association with intrauterine HBV infection. We analyzed HBV replication status in PBMC and PC/BCP mutants in PBMC from pregnant chronic hepatitis B (CHB) patients. METHODS: Pregnant CHB carriers were assessed for HBeAg, HBV-DNA, ALT in second-third trimester and liver stiffness measurement (LSM) postpartum. HBV-DNA, HBV-cccDNA, and HBV-mRNA were tested in PBMC by in-house PCR. BCP/PC variants were determined by Sanger sequencing and analyzed using MEGA7. RESULTS: In 37 CHB pregnant carriers, median age 32 years, 53% Asian, median ALT 19 versus 26 U/L, median HBV-DNA 2.6 versus 8.1 logIU/mL (untreated vs. treated), eight HBeAg+, with genotype 10%A, 29%B, 21%C, 10%D, 19%E, eight received tenofovir in pregnancy to reduce vertical transmission risk. HBV-DNA was detected in ~ 55% (25/45) PBMC, and PC/BCP mutations were found in 36% (9/25) and 4% (1/25), respectively. All infants received HBV immunoprophylaxis and tested HBV surface antigen negative at 9-12 months of age. During a median 4 years (IQR 3-5), follow-up all mothers showed normal LSM, with no significant change in ALT, HBeAg status, or HBV-DNA levels compared to baseline in untreated CHB carriers. CONCLUSION: In this multiethnic cohort of pregnant CHB carriers, HBV replicative intermediates and PC/BCP mutants were found in significant proportion of PBMC, but were not associated with increased risk of HBV immunoprophylaxis failure or liver disease severity over long-term follow-up.
PURPOSE: HBV precore (PC) and basal core promoter (BCP) mutants are associated with liver disease severity, yet have been suggested to protect against HBV vertical transmission. HBV within peripheral blood mononuclear cells (PBMC) has been reported in association with intrauterine HBV infection. We analyzed HBV replication status in PBMC and PC/BCP mutants in PBMC from pregnant chronic hepatitis B (CHB) patients. METHODS: Pregnant CHB carriers were assessed for HBeAg, HBV-DNA, ALT in second-third trimester and liver stiffness measurement (LSM) postpartum. HBV-DNA, HBV-cccDNA, and HBV-mRNA were tested in PBMC by in-house PCR. BCP/PC variants were determined by Sanger sequencing and analyzed using MEGA7. RESULTS: In 37 CHB pregnant carriers, median age 32 years, 53% Asian, median ALT 19 versus 26 U/L, median HBV-DNA 2.6 versus 8.1 logIU/mL (untreated vs. treated), eight HBeAg+, with genotype 10%A, 29%B, 21%C, 10%D, 19%E, eight received tenofovir in pregnancy to reduce vertical transmission risk. HBV-DNA was detected in ~ 55% (25/45) PBMC, and PC/BCP mutations were found in 36% (9/25) and 4% (1/25), respectively. All infants received HBV immunoprophylaxis and tested HBV surface antigen negative at 9-12 months of age. During a median 4 years (IQR 3-5), follow-up all mothers showed normal LSM, with no significant change in ALT, HBeAg status, or HBV-DNA levels compared to baseline in untreated CHB carriers. CONCLUSION: In this multiethnic cohort of pregnant CHB carriers, HBV replicative intermediates and PC/BCP mutants were found in significant proportion of PBMC, but were not associated with increased risk of HBV immunoprophylaxis failure or liver disease severity over long-term follow-up.
Authors: Golasa Samadi Kochaksaraei; Stephen E Congly; Trudy Matwiy; Eliana Castillo; Steven R Martin; Carmen L Charlton; Carla S Coffin Journal: Liver Int Date: 2016-05-13 Impact factor: 5.828
Authors: Anders Eilard; Maria Andersson; Johan Ringlander; Rune Wejstål; Gunnar Norkrans; Magnus Lindh Journal: J Infect Date: 2019-01-16 Impact factor: 6.072
Authors: Dan Dan Wang; Lin Zhu Yi; Li Na Wu; Zhi Qing Yang; Hai Yun Hao; Xiao Hong Shi; Bo Wang; Shu Ying Feng; Yong Liang Feng; Su Ping Wang Journal: Biomed Environ Sci Date: 2019-05 Impact factor: 3.118
Authors: Giovanni Raimondo; Stephen Locarnini; Teresa Pollicino; Massimo Levrero; Fabien Zoulim; Anna S Lok Journal: J Hepatol Date: 2019-04-18 Impact factor: 25.083
Authors: William S Mason; Upkar S Gill; Samuel Litwin; Yan Zhou; Suraj Peri; Oltin Pop; Michelle L W Hong; Sandhia Naik; Alberto Quaglia; Antonio Bertoletti; Patrick T F Kennedy Journal: Gastroenterology Date: 2016-07-22 Impact factor: 22.682